Globally known professor and dermatologist joins LEO Pharma
Privately-held Danish dermatology specialist LEO Pharma has named Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new vice president, head of global medical affairs.
Prof Egeberg will start in his new role January 1, 2024, reporting to Becki Morison, executive VP global product strategy and international operations with LEO Pharma.
Prof Egeberg joins LEO Pharma from a role as professor of dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology. Having authored over 300 international scientific publications, he is an expert in inflammatory skin diseases with extensive experience in epidemiology, real-world evidence, translational medicine, and clinical trials. In addition, he has through his work in medical affairs at Pfizer (NYSE: PFE) and as a consultant for additional global pharma companies built a solid understanding of corporate pharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze